Compare Vanguard Growth Index Fund ETF (VUG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Growth Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Growth Index Fund ETF trades at $88.89, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| VUG | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $90.29 | $164.28 |
52-Week Low | $70.00 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUG trades at $88.94, down 0.27% on the day, with a bullish technical signal driven by moving averages. The ETF shows strong institutional accumulation, with multiple firms increasing holdings by over 500% in Q2 2026. RSI levels above 70 indicate potential overbought conditions, while support sits near $88 and resistance at $90.
The outlook remains positive given institutional confidence and growth ETF appeal, but high RSI suggests near-term consolidation risk. Investors face volatility from market sentiment shifts, though long-term growth exposure aligns with historical outperformance versus the S&P 500.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
